Market Overview

The Neurodegenerative Disease Therapeutics Market was valued at US$ 12.52 billion in 2024 and is projected to reach US$ 28.78 billion by 2033, registering a CAGR of 9.8% throughout the forecast period 2025 to 2033. The Neurodegenerative Disease Therapeutics Market is surging with rising approvals for drugs targeting Alzheimer's, Parkinson's, and ALS. Aging populations worldwide amplify demand for effective symptom management and disease-modifying therapies. Innovations in gene therapies and immunomodulators are reshaping treatment landscapes.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/neurodegenerative-disease-therapeutics-market

Market Drivers

Escalating prevalence of disorders like Alzheimer's and Parkinson's among seniors fuels therapeutic needs. Regulatory approvals for novel drugs such as QALSODY and OCREVUS accelerate market entry. Substantial R&D investments by governments and pharma firms support pipeline development. Advances in oral and injectable routes enhance patient compliance and efficacy.

Market Restraints

Side effects from therapies like dopamine agonists deter widespread use and adherence. High development costs for complex biologics limit accessibility in emerging markets. Stringent regulatory hurdles delay approvals for innovative treatments. Limited efficacy in late-stage diseases challenges market expansion.

Market Geographical Share

North America secures 37.6% share in the Neurodegenerative Disease Therapeutics Market, propelled by high prevalence and NIH funding for research. The United States dominates with biotech hubs and trials for new drugs. Europe grows with approvals like PRODUODOPA for Parkinson's in advanced cases. Asia-Pacific, at 22.8%, emerges fastest due to aging in China and Japan alongside local innovations. Latin America and Middle East & Africa show gradual uptake through global partnerships.

Market Segments

By Drug Class

• Dopamine Agonists

• Decarboxylase Inhibitors

• Cholinesterase Inhibitors

• Immunomodulators

• Others

By Disease Type

• Parkinson’s Disease

• Amyotrophic Lateral Sclerosis

• Alzheimer’s Disease

• Huntington Disease

• Others

By Route of Administration

• Oral

• Injection

• Transdermal

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Market Key Players

Key players are AbbVie Inc., Amneal Pharmaceuticals LLC., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Ltd., Orion Corporation.

Latest Developments

Supernus Pharmaceuticals gained FDA approval for ONAPGO infusion in February 2025, revolutionizing Parkinson's motor management. Eisai and Biogen approved LEQEMBI maintenance dosing in January 2025 for Alzheimer's mild stages. Novartis licensed PTC518 from PTC Therapeutics in December 2024 for Huntington's oral therapy. AbbVie reported positive TEMPO-1 trial results for tavapadon in September 2024, advancing early Parkinson's treatment. Teva launched AUSTEDO XR in May 2024 for dyskinesia and chorea.

About DataM Intelligence 4Market Research

DataM Intelligence 4Market Research is a market intelligence platform that gives access to syndicated, customized reports and consulting to its clients in one place. As a firm with rich experience in research and consulting across multiple domains, we are a one-stop solution that will cater to the needs of clients in key business areas. DataM Intelligence has an online platform whose coverage includes industries such as chemicals and materials, agriculture, health care services, animal feed, and food & beverages among others. Our platform has Insights on markets that uncover the latest market research data that are distinct from the competition. With coverage across 10 major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the market, by providing a complete view of the market with statistical forecasts. Our strategy-centric framework and value-added services will let individuals and corporates with ease of access and custom personalization to research and markets.

Key Highlights of Report

Market Growth: The Neurodegenerative Disease Therapeutics Market is projected to grow at a CAGR of 9.8% during 2025-2033. North America Dominance: North America leads with 37.6% share, driven by AbbVie and funding boosts. Dopamine Agonists Prevail: This class holds 24.8% share for Parkinson's symptom control. Alzheimer's Applications Lead: Alzheimer's therapeutics dominate due to high incidence. Innovative Approvals: Recent FDA nods enhance treatment options. COVID-19 Impact: Pandemic spurred research into neurological effects.

Conclusion

The Neurodegenerative Disease Therapeutics Market exhibits robust growth, driven by innovative drugs meeting aging-related demands. Enhanced therapies promise improved quality of life for affected individuals